--- title: "ZAWYA-PRESSR: Mubadala Bio acquires full ownership of IDS and GMSC" type: "News" locale: "en" url: "https://longbridge.com/en/news/276104719.md" description: "Mubadala Bio has completed the full acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) from Yas Holding’s GlobalOne Healthcare Holding, following an initial 80% acquisition in 2024. This move aims to enhance the UAE's life sciences ecosystem by integrating biopharmaceutical manufacturing and logistics, ensuring drug security and efficient healthcare product availability. Dr. Bakheet Al Katheeri emphasized the importance of this strategic acquisition for national healthcare resilience, while Yas Holding's CEO highlighted the operational capabilities of IDS and GMSC in supporting Mubadala Bio's growth." datetime: "2026-02-17T08:15:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276104719.md) - [en](https://longbridge.com/en/news/276104719.md) - [zh-HK](https://longbridge.com/zh-HK/news/276104719.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276104719.md) | [繁體中文](https://longbridge.com/zh-HK/news/276104719.md) # ZAWYA-PRESSR: Mubadala Bio acquires full ownership of IDS and GMSC **Abu Dhabi:** Mubadala Bio, a life sciences company committed to advancing better health outcomes for the UAE and beyond, announced that it has finalized the full acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) from Yas Holding’s GlobalOne Healthcare Holding, following the initial 80% acquisition at the end of 2024. The completion of this transaction reflects Mubadala Bio’s continued progress in building a vertically integrated life sciences platform in the UAE. By bringing together biopharmaceutical manufacturing and pharmaceutical logistics under a unified strategy, the company is reinforcing its commitment to strengthening the national life sciences ecosystem. Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio said: “This strategic move supports Mubadala Bio’s vertical integration strategy, creating greater efficiency and stronger coordination across the life sciences value chain. It also reinforces national drug security by ensuring essential healthcare products are consistently available across the UAE.” **Low Ping, Group CEO of Yas Holding, commented:** “We are pleased to confirm Mubadala Bio’s full ownership and control of IDS and GMSC. The proven capability and reach of both companies will help ensure resilience and efficiency not just across Mubadala Bio’s growing life sciences platform, but also our national healthcare supply chain”. Through full ownership of IDS and GMSC, Mubadala Bio advances its mission to strengthen national drug security, reinforce critical pharmaceutical distribution networks, and help build a robust, integrated life sciences ecosystem that supports the UAE’s ambition for a resilient, innovation-driven healthcare sector. **About Mubadala Bio** Mubadala Bio is a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. As a catalyst for progress and innovation, we are accelerating the growth of the life sciences ecosystem by enhancing drug security and expanding access to affordable, essential treatments. Operating through two core verticals, Integrated Biopharma and Pharma Logistics, we are advancing local pharmaceutical manufacturing while ensuring timely access to critical and lifesaving medications. With a growing footprint across the UAE, Asia, Africa, and Europe, we are driving impact both locally and globally. Our portfolio focuses on key therapy areas that address some of the world’s most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support, and complementary medicine. Headquartered in Abu Dhabi and wholly owned by Mubadala Investment Company, we are fostering innovation, cultivating local talent, and helping build a knowledge-based economy – delivering better health, closer for all. Learn more at www.mubadalabio.ae **About Yas Holding** Yas Holding is a renowned UAE investment company with a multi-industry business portfolio, committed to driving performance and unlocking tangible value in local and international markets. From healthcare to aviation, technology and real estate, we adopt a strategic investment approach, focusing on sectors of tomorrow and driving innovation in areas which contribute to wellbeing, security and sustainable growth. Through our diverse investments and operating companies, we are committed to supporting the development of the UAE and the markets and communities we serve. Send us your press releases to pressrelease.zawya@lseg.com Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release. The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk. To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages. ## Related News & Research - [03:02 ETSyneron Bio Announces Completion of $150 Million Series B Financing](https://longbridge.com/en/news/281612425.md) - [08:30 ETXtalks Announces its Life Science Webinar Calendar for April 2026](https://longbridge.com/en/news/281367988.md) - [Merck KGaA Completes Purchase of JSR Life Sciences' Chromatography Unit](https://longbridge.com/en/news/281371096.md) - [08:46 ETIntercon Chemical Debuts Medical Device and Life Sciences Cleaning Brands Cleaner MD and Cleaner LS](https://longbridge.com/en/news/281526711.md) - [Blackstone announces final close of record $6.3 billion life sciences fund - the largest private fund dedicated to life sciences](https://longbridge.com/en/news/281041966.md)